Moleculin Biotech, Inc.

Moleculin Biotech, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Moleculin Biotech, Inc. has 7.10M shares outstanding.

As of June 30, 2026, Moleculin Biotech, Inc. maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -142.11, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Moleculin Biotech, Inc.'s stock has declined approximately 99.67% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Moleculin Biotech, Inc. generated - - in revenue and converted that into -26.55M in net income, yielding earnings per share of -9.27. EBITDA reached -25.23M, while operating income came in at -25.27M.

As of June 30, 2026, Moleculin Biotech, Inc. holds 6.36M in cash and equivalents against 255,587.60 in total debt, resulting in a net debt position of -6.36M. Total book value stands at 10.14M, with working capital of -516,427.00 providing operational flexibility.

Moleculin Biotech, Inc. produced -22.19M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -22.19M - equivalent to -7.75 per share.

Moleculin Biotech, Inc.'s most recent stock split took place on October 20, 2026 with a 20:1 split ratio.